TMCnet News
Grafix® Cost Comparative Manuscript Reporting Wound Care Cost Reduction is Available Electronically in a Peer-Reviewed JournalCOLUMBIA, Md., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopaedics, and sports medicine, announced today that a new peer-reviewed manuscript “Innovative Treatment of Chronic Diabetic Foot Ulcer in a Controlled Randomized Clinical Trial Produces Fewer Adverse Events, Faster Wound Closure, and Lower Costs” has been published in the Journal of Clinical Diabetes and Practice and is available online. A cost comparative model was applied to patient data from the Grafix multicenter, controlled, randomized, blinded, clinical trial for chronic diabetic foot ulcers (DFUs) (Lavery et al., Int Wound J, 2014, 11: 554-560) by investigators at the Division of Health Care Policy and Research at the University of Colorado, Anschutz Medical Campus. This group evaluated the cost effectiveness and cost benefits of Grafix compared to Good Wound Care (GWC). Data demonstrated that the use of Grafix for the treatment of chronic DFUs is cost effective in comparison to GWC. The estimated savings during the trial based on associated adverse events and serious adverse events were approximately $14,000/patient. There were no Grafix-related reportable adverse or serious adverse events during the trial. When closed and non-closed wounds were compared, the estimated cost savings for closed wounds were also approximately $14,000/patient. Overall, lower costs were associated with patients managed with Grafix, and these patients experienced fewr adverse events, fewer serious adverse events, and fewer hospitalizations due to faster wound closure. “A DFU is a common complication of diabetes that is costly to treat. Poor or ineffective management of such wounds will lead to the use of intensive services, thus further increasing cost. Cost effectiveness should be an integral part for assessments of all wound care treatment modalities,” says Dr. Eugene J. Nuccio, an Assistant Professor within the Division of Health Care Policy and Research at the University of Colorado, Anschutz Medical Campus, the Principal Investigator of the Grafix cost comparative analysis. “We were very pleased to see significant reduction of wound related infections in the Grafix DFU trial,” said Dr. Lawrence Lavery, D.P.M., M.P.H., a Principal Investigator and Professor of Plastic Surgery, University of Texas Southwestern Medical Center. “The outcome of this study is critical evidence for every wound care provider and payer to consider. This study shows that adding Grafix in addition to GWC prevents adverse events and reduces the overall cost of care.” About Grafix About Osiris Therapeutics Forward-Looking Statements
For additional information, please contact: Diane Savoie Osiris Therapeutics, Inc. (443) 545-1834 [email protected] |